Insider Transactions in Q1 2021 at Arrowhead Pharmaceuticals, Inc. (ARWR)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 22
2021
|
Douglas B Given Director |
SELL
Open market or private sale
|
Indirect |
1,125
-7.5%
|
$99,000
$88.73 P/Share
|
|
Feb 08
2021
|
Patrick O'Brien COO and General Counsel |
SELL
Open market or private sale
|
Direct |
90,000
-6.35%
|
$7,920,000
$88.34 P/Share
|
|
Feb 08
2021
|
Patrick O'Brien COO and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
90,000
+19.01%
|
$450,000
$5.22 P/Share
|
|
Jan 15
2021
|
Douglas B Given Director |
SELL
Open market or private sale
|
Indirect |
3,000
-19.35%
|
$249,000
$83.28 P/Share
|
|
Jan 14
2021
|
James C Hamilton Chief Discovery/Trans Medicine |
SELL
Open market or private sale
|
Direct |
10,000
-3.74%
|
$810,000
$81.4 P/Share
|
|
Jan 12
2021
|
Kenneth Allen Myszkowski Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,441
-0.32%
|
$116,721
$81.0 P/Share
|
|
Jan 11
2021
|
Kenneth Allen Myszkowski Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,597
-2.54%
|
$939,357
$81.02 P/Share
|
|
Jan 07
2021
|
James Hassard Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
15,625
-12.5%
|
$1,171,875
$75.0 P/Share
|
|
Jan 06
2021
|
Kenneth Allen Myszkowski Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
30,625
-2.11%
|
$2,174,375
$71.72 P/Share
|
|
Jan 06
2021
|
Patrick O'Brien COO and General Counsel |
SELL
Open market or private sale
|
Direct |
25,000
-2.67%
|
$1,775,000
$71.91 P/Share
|
|
Jan 06
2021
|
James C Hamilton Chief Discovery/Trans Medicine |
SELL
Open market or private sale
|
Direct |
19,375
-4.25%
|
$1,375,625
$71.87 P/Share
|
|
Jan 05
2021
|
James C Hamilton Chief Discovery/Trans Medicine |
SELL
Open market or private sale
|
Direct |
19,375
-2.87%
|
$1,395,000
$72.53 P/Share
|
|
Jan 04
2021
|
William D. Waddill Director |
SELL
Open market or private sale
|
Direct |
3,750
-11.03%
|
$285,000
$76.08 P/Share
|
|
Jan 04
2021
|
Douglas B Given Director |
SELL
Open market or private sale
|
Direct |
4,000
-3.24%
|
$304,000
$76.08 P/Share
|
|
Jan 04
2021
|
Michael S Perry Director |
SELL
Open market or private sale
|
Direct |
4,000
-4.26%
|
$304,000
$76.09 P/Share
|
|
Jan 01
2021
|
William D. Waddill Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+20.93%
|
-
|
|
Jan 01
2021
|
James C Hamilton Chief Discovery/Trans Medicine |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+22.22%
|
-
|
|
Jan 01
2021
|
Douglas B Given Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,500
+7.15%
|
-
|
|
Jan 01
2021
|
Michael S Perry Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+8.74%
|
-
|
|
Jan 01
2021
|
Adeoye Y Olukotun Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+39.13%
|
-
|
|
Jan 01
2021
|
Kenneth Allen Myszkowski Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+10.96%
|
-
|
|
Jan 01
2021
|
Marianne De Backer Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+25.35%
|
-
|
|
Jan 01
2021
|
Mauro Ferrari Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+18.38%
|
-
|
|
Jan 01
2021
|
Patrick O'Brien COO and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+15.86%
|
-
|
|
Jan 01
2021
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
800,000
+19.3%
|
-
|